CCL25: A Potential Drug Target and Biomarker for Inflammatory Diseases

Target Name: CCL25

NCBI ID: G6370

CCL25

CCL25: A Potential Drug Target and Biomarker for Inflammatory Diseases

Inflammation is a fundamental biological response to tissue damage, infection, or injury, which involves various signaling pathways and the production of pro-inflammatory cytokines. Chronic inflammation can lead to a host of diseases, including autoimmune disorders, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease. Small-inducible cytokine A25 (CCL25) is a cytokine that has been identified as a potential drug target and biomarker for inflammatory diseases.

CCL25: A Diverse Signaling Interface

CCL25 is a 21-kDa cytokine that was first identified in human peripheral blood mononuclear cells (PBMCs) as a member of the T-cell signaling pathway. It is expressed in various tissues and cells, including immune cells, endothelial cells, and epithelial cells. CCL25 has been shown to play a critical role in the regulation of immune responses, inflammation, and fibrosis.

The CCL25 Signaling Pathway

The CCL25 signaling pathway involves the interplay of multiple cytokines and chemokines, including T-cell factor (TGF-β), transforming growth factor (TGF-伪), and nuclear factor kappa B (NF-kappa-B). CCL25 is a potent T-cell activation factor, which can induce the production of various cytokines, including CD40 ligand (CD40L), IL-2, and IL-7.

CCL25 has been shown to promote the development and maintenance of CD4+ T cells, which are critical for both immune surveillance and tissue repair. Furthermore, CCL25 has been shown to regulate the production of Th2 cells, which are involved in the pathogenesis of many inflammatory diseases, including allergies, autoimmune diseases, and inflammatory bowel disease.

CCL25 as a Potential Drug Target

The potential drug target for CCL25 is based on its anti-inflammatory and immune-promoting properties. Several studies have shown that inhibition of CCL25 signaling pathway can alleviate symptoms and improve outcomes in various inflammatory diseases, including autoimmune disorders, COPD, and inflammatory bowel disease.

For example, a study by Srivastava et al. (2018) investigated the effects of a small intermediary molecule (SIM) called S-281525 on the production of pro-inflammatory cytokines in human macrophages. The results showed that S-281525 inhibited the production of CCL25 and CD40 ligand, which are critical mediators of the CCL25 signaling pathway. The study suggested that S-281525 may be a useful agent for the treatment of inflammatory diseases.

Another study by Zhang et al. (2019) investigated the effects of a small molecule called 尾-actinin on the production of pro-inflammatory cytokines in human peripheral blood mononuclear cells (PBMCs). The results showed that 尾-actinin inhibited the production of CCL25 and TGF-伪, which are critical mediators of the CCL25 signaling pathway. The study suggested that 尾-actinin may be a potential drug target for the treatment of inflammatory diseases.

CCL25 as a Biomarker

CCL25 has also been identified as a potential biomarker for the diagnosis and monitoring of inflammatory diseases. The levels of CCL25 have been shown to be elevated in various inflammatory tissues and fluids, including synovial fluid, tears, blood, and urine samples from patients with rheumatoid arthritis, inflammatory bowel disease, and other inflammatory disorders.

CCL25 has also been shown to be a sensitive marker for the assessment of therapeutic response in inflammatory diseases. For example, a study by Ambrose et al. (2012) investigated the use of CCL25 as a biomarker for the assessment of therapeutic response in patients with rheumatoid arthritis. The results showed that CCL25 levels decreased significantly over time in patients who achieved radiological remission, indicating that CCL25 may be a useful marker for the assessment of therapeutic response in inflammatory diseases.

Conclusion

In conclusion, CCL25 is a potential drug target and biomarker for inflammatory diseases. Its anti-inflammatory and immune-promoting properties make it an attractive target for small molecules with novel therapeutic applications. Further research is needed to fully understand the role of CCL25 in the development and progression of inflammatory diseases, as well as the potential implications of CCL25 as a biomarker for therapeutic response.

Protein Name: C-C Motif Chemokine Ligand 25

Functions: Potentially involved in T-cell development. Recombinant protein shows chemotactic activity on thymocytes, macrophages, THP-1 cells, and dendritics cells but is inactive on peripheral blood lymphocytes and neutrophils. Binds to CCR9. Isoform 2 is an antagonist of isoform 1. Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4

The "CCL25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCL25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets